Assembly Biosciences, Inc. Current Liabilities
Assembly Biosciences, Inc. (ASMB) had Current Liabilities of $23.45 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Liabilities, Current $23.45M.
- 2026-03-31: Liabilities, Current $35.00M.
- 2025-12-31: Liabilities, Current $48.78M.
- 2025-09-30: Liabilities, Current $53.38M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $23.45M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $35.00M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $48.78M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $53.38M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $47.29M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $46.63M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $47.80M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $41.63M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $41.27M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $38.75M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $39.23M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $7.13M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $8.83M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $9.97M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $16.30M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $15.46M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $14.96M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $10.71M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $16.07M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $14.93M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $13.91M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $14.50M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $24.43M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $16.80M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $17.27M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $21.15M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $24.44M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $21.50M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $19.93M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $25.20M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $18.47M 10-K · filed 2020-03-04 | |
| 2018-09-30 | $14.61M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $13.13M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $12.18M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $13.49M 10-K · filed 2019-02-28 | $13.49M 10-K · filed 2018-03-08 |
| 2017-09-30 | $12.22M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $11.99M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $10.96M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $7.12M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $7.48M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $5.04M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $3.57M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $3.40M 10-K · filed 2017-03-02 | |
| 2015-09-30 | $2.65M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $2.24M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $2.13M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $1.05M 10-K · filed 2016-03-11 | |
| 2014-09-30 | $1.05M 10-Q · filed 2014-11-17 | |
| 2013-12-31 | $2.64M 10-K · filed 2015-03-16 | |
| 2012-09-30 | $2.68M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $3.39M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $3.85M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $2.51M 10-Q · filed 2012-11-13 | |
| 2011-09-30 | $1.18M 10-Q/A · filed 2011-11-18 | |
| 2011-06-30 | $769.94K 10-Q · filed 2011-08-15 | |
| 2010-12-31 | $1.72M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |